Clinical Pharmacokinetics of Approved RNA Therapeutics
International Journal of Molecular Sciences · 01.01.2023 · 24 (1) · 746
DOI: 10.3390/ijms24010746 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 01.01.2023. Verfasst von Seong Jun Jo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Integrated Research Institute of Pharmaceutical Sciences, College of Pharmacy, The Catholic University of Korea, Bucheon 14662, Republic of Korea. Hauptthemen laut MEDLINE: Pharmacokinetics. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), Basic Science Research Program through the National Research Foundation of Korea, Research Fund of The Catholic University of Korea.
Abstract (Originalsprache)
RNA-mediated drugs are a rapidly growing class of therapeutics. Over the last five years, the list of FDA-approved RNA therapeutics has expanded owing to their unique targets and prolonged pharmacological effects. Their absorption, distribution, metabolism, and excretion (ADME) have important clinical im-plications, but their pharmacokinetic properties have not been fully understood. Most RNA therapeutics have structural modifications to prevent rapid elimination from the plasma and are administered intravenously or subcutaneously, with some exceptions, for effective distribution to target organs. Distribution of drugs into tissues depends on the addition of a moiety that can be transported to the target and RNA therapeutics show a low volume of distribution because of their molecular size and negatively-charged backbone. Nucleases metabolize RNA therapeutics to a shortened chain, but their metabolic ratio is relatively low. Therefore, most RNA therapeutics are excreted in their intact form. This review covers not only ADME features but also clinical pharmacology data of the RNA therapeutics such as drug–drug interaction or population pharmacokinetic analyses. As the market of RNA therapeutics is expected to rapidly expand, comprehensive knowledge will contribute to interpreting and evaluating the pharmacological properties.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Integrated Research Institute of Pharmaceutical Sciences, College of Pharmacy, The Catholic University of Korea, Bucheon 14662, Republic of Korea.
ORCID-Profile: Soo Kyung Bae
Förderung
- Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI)
- Basic Science Research Program through the National Research Foundation of Korea
- Research Fund of The Catholic University of Korea
- National Research Foundation of Korea
- Ministry of Health & Welfare
Zitieren
APA
Jo, S. J., Chae, S. U., Lee, C. B., & Bae, S. K. (2023). Clinical Pharmacokinetics of Approved RNA Therapeutics. International Journal of Molecular Sciences, 24(1), 746. https://doi.org/10.3390/ijms24010746
Vancouver
Jo SJ, Chae SU, Lee CB, Bae SK. Clinical Pharmacokinetics of Approved RNA Therapeutics. International Journal of Molecular Sciences. 2023;24(1):746. doi:10.3390/ijms24010746
BibTeX
@article{Jo2023,
author = {Jo, Seong Jun and Chae, Soon Uk and Lee, Chae Bin and Bae, Soo Kyung},
title = {Clinical Pharmacokinetics of Approved RNA Therapeutics},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {1},
pages = {746},
doi = {10.3390/ijms24010746}
}
EUVIMED